BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial f…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | — | — |
| Estimado | $-0.77 | $-0.30 | $-1.04 | $-0.77 |
| Sorpresa | — | — | — | — |
| Métrica | BLRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 80.5% | 57.4% | +23.1% |
| Operating Margin | -871.8% | -34.4% | -837.4% |
| Net Margin | -171.7% | -32.5% | -139.2% |
| FCF Margin | -686.4% | -12.6% | -673.8% |
| ROE | -11.1% | -39.2% | +28.0% |
| ROA | -5.0% | -30.9% | +26.0% |
| Current Ratio | 1.95 | 2.73 | -0.78 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -5.0% | — |
| ✗Flujo de caja operativo positivo | −$8M | −$44M |
| ✓Rentabilidad sobre activos al alza | -5.0% | -23.7% |
| ✗Caja operativa/activos supera al ROA | -19.7% | ROA -5.0% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.95 | 1.76 |
| ✗Sin aumentar el nº de acciones | 2,465M | 1,198M |
| ✓Margen bruto al alza | 80.5% | 68.0% |
| ✗Rotación de activos al alza | 0.03 | 0.74 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -686.4% |
| ✗ROCE > 10 % | -35.7% |
| ✓Deuda neta/EBITDA < 3x | -0.1x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 688.0% |
BioLineRx Ltd. cotiza a 2.01 USD y tiene una capitalización bursátil de $10M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud